United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Application n° US17072430, December 12, 2023, Publication Number: US11839631B2. The news was reported in the Magazine “Pharmaceutical Technology, April 4, 2024. To be followed! Read more at this link on the […]

United Therapeutics has been granted a patent for a method to treat pulmonary arterial hypertension (PAH) by administering endothelial progenitor cells treated with prostacyclin Read Post »

Driving innovation and patient-centred care in pulmonary hypertension: the inspiring journey of Dr. Joanna Pepke-Zaba, March 28, 2024

Dr. Joanna Pepke-Zaba, renowned consultant respiratory physician at Royal Papworth Hospital, recently received a prestigious European Respiratory Society (ERS) lifetime achievement award, marking another milestone in her illustrious career. In an interview with Saša Janković, recently published on March 18, 2024 on “Hospital Health Care Europe”, Dr. Pepke-Zaba discusses her dedication to advancing research and

Driving innovation and patient-centred care in pulmonary hypertension: the inspiring journey of Dr. Joanna Pepke-Zaba, March 28, 2024 Read Post »

Outsanding scientific program for the French Pulmonary Hypertension Association’s Annual General Assembly, April 6 2024

The Annual General Assembly of the French Pulmonary Hypertension Association HTaPFrance is taking place in Paris on Saturday the 6th of April 2024 in Paris. The morning program is dedicated to the presentation of the annual report of activities, vote on financial report and approval of new members of the Board. The afternoon program features

Outsanding scientific program for the French Pulmonary Hypertension Association’s Annual General Assembly, April 6 2024 Read Post »

The US Food and Drug Administration, FDA, approves sotatercept, Merck’s new drug for pulmonary arterial hypertension, March 26, 2024

The US Food and Drug Administration has approved sotatercept, Merck‘s new drug for pulmonary arterial hypertension. It’s commercial name is Winrevair. Read more on the FDA website at this link Sotatercept is an activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein. It was evaluated as an add-on to stable background therapy for the treatment of pulmonary

The US Food and Drug Administration, FDA, approves sotatercept, Merck’s new drug for pulmonary arterial hypertension, March 26, 2024 Read Post »

Proud and honoured to introduce the Alliance for Pulmonary Hypertension’s Scientific Committee

The Alliance for Pulmonary Hypertension is very honoured to present its Scientific Committee, featuring some of the world’s most renowned experts in the field of pulmonary hypertension. The Scientific Committee will play a pivotal role in supporting the Alliance’s mission to share knowledge and expertise about pulmonary hypertension via its Pulmonary Hypertension Knowledge Sharing Platform.

Proud and honoured to introduce the Alliance for Pulmonary Hypertension’s Scientific Committee Read Post »

Gas-filled balloon implanted in main pulmonary artery to alleviate right ventricle workload tested in pulmonary hypertension

The Aria CV Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heart failure. An article published in the European Journal of Heart Failure on March 13, 2024 titled “Efficacy and safety of the

Gas-filled balloon implanted in main pulmonary artery to alleviate right ventricle workload tested in pulmonary hypertension Read Post »

John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease, London, March 15-16, 2024

The first John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease was held in London, UK, 2006 to honour the memory of Sir John Vane, the founder of the William Harvey Research Institute and Nobel prize Laureate for his discovery of prostacyclin and its analogues (see also our article at this link). It

John Vane Memorial Symposium on Prostacyclin Science and Pulmonary Vascular Disease, London, March 15-16, 2024 Read Post »

Multinational real-world survey offers insights into key factors in delays to diagnosis for pulmonary arterial hypertension patients, Therapeutic Advances in Respiratory Disease, February 2024

Delays to diagnosis in pulmonary arterial hypertension still persist today, despite the substantial progress made in the field. This ongoing issue continues to pose a significant challenge, highlighting the need for continued efforts to improve early detection and intervention strategies. Delays in diagnosis not only prolong patient suffering but also lead to missed opportunities for

Multinational real-world survey offers insights into key factors in delays to diagnosis for pulmonary arterial hypertension patients, Therapeutic Advances in Respiratory Disease, February 2024 Read Post »

Launched today, Rare Disease Day 2024, the PHA Europe “BEL AIR” virtual conference center for pulmonary hypertension

The BEL AIR CENTER is a virtual conference center, divided into several “rooms” where visitors can find and view presentations from leading pulmonary hypertension experts and from PHA Europe’s industry partners, patient association information booths, an art gallery with works by patients and health care professionals, and a networking café. Prof. Marc Humbert, Director of

Launched today, Rare Disease Day 2024, the PHA Europe “BEL AIR” virtual conference center for pulmonary hypertension Read Post »

Coming up soon, the World Symposium on Pulmonary Hypertension 2024, the most important scientific event in the world this field!

The 7th edition of the World Symposium on Pulmonary Hypertension is being held on June 29-30/July 1, 2024, in Barcelona, Spain. The WSPH is the most important scientific event in the field of pulmonary hypertension. It has been convened every five years since the Evian edition in 1998 (including Venice 2003, Dana Point 2008, Nice

Coming up soon, the World Symposium on Pulmonary Hypertension 2024, the most important scientific event in the world this field! Read Post »

Why the recent US revision of the ICD-10-CM to include codes for lung allograft dysfunction matters for pulmonary arterial hypertension

The International Classification of Diseases (ICD) is a medical coding system crafted by the World Health Organization (WHO). It serves as the primary foundation for health recording and disease statistics across various levels of care, including primary, secondary, and tertiary care settings, as well as on death certificates to determine causes of mortality. These meticulously

Why the recent US revision of the ICD-10-CM to include codes for lung allograft dysfunction matters for pulmonary arterial hypertension Read Post »

Cereno Scientific announces FDA approval for expanded access to investigational pulmonary arterial hypertension drug CS1

Cereno Scientific announced on January 31, 2024 that it has received approval from the US Food and Drug Administration (FDA) for expanded access to the investigational drug CS1 in the ongoing Phase II trial for pulmonary arterial hypertension (PAH). This program allows patients who completed the Phase II to continue CS1 therapy. Positive outcomes from

Cereno Scientific announces FDA approval for expanded access to investigational pulmonary arterial hypertension drug CS1 Read Post »

“EXPOSURE” study provides insights into real-world management and outcomes of patients with pulmonary arterial hypertension -“Advances in Therapy”, January 13,2024

“EXPOSURE” (EUPAS19085) is an observational study describing the characteristics, treatment patterns, and outcomes of patients with pulmonary arterial hypertension initiating a new specific therapy in Europe/Canada. In total, 1.944 patients with follow-up information were included. Most study patients were female with WHO functional class II/III symptoms and idiopathic or connective tissue disorder-associated pulmonary arterial hypertension.

“EXPOSURE” study provides insights into real-world management and outcomes of patients with pulmonary arterial hypertension -“Advances in Therapy”, January 13,2024 Read Post »

“How your patient is really feeling: the emotional hinterland of a cardiac diagnosis”, European Heart Journal, 8 January 2024

The authors of this article, titled “How your patient is really feeling: the emotional hinterland of a cardiac diagnosis“, published on the European Heart Journal on January 8, 2024, focus on the impact of receiving and living with a cardiac disease diagnosis, and in particular to the psychosocial aspects, which, they say, continue to be underrepresented in

“How your patient is really feeling: the emotional hinterland of a cardiac diagnosis”, European Heart Journal, 8 January 2024 Read Post »

Prof. Adam Torbicki explores access to care, Prof. Jean-Luc Vachiéry delves into drug development – watch the highlights from the PHA Europe Annual Conference online

Prof. Adam Torbicki’s presentation is titled “Access to care for pulmonary arterial hypertension and chronic thromboembolic pulmponary hypertension”. It can be viewed at this link on Vimeo (you need to register on Vimeo to see it) Prof. Jean-Luc Vachiéry’s presentation is titled “Drug development and clinical trials“. It can be viewed at this link on

Prof. Adam Torbicki explores access to care, Prof. Jean-Luc Vachiéry delves into drug development – watch the highlights from the PHA Europe Annual Conference online Read Post »

Why quality indicators for pulmonary hypertension care are important from a patient perspective, Pisana Ferrari

It was a great honour to be invited to speak at the ERN-LUNG webinar on quality indicators for adult pulmonary arterial hypertension care, which took place on December 8, 2023, where I was asked to explain why these are important from a patient perspective. The webinar referenced an article in the European Journal of Heart

Why quality indicators for pulmonary hypertension care are important from a patient perspective, Pisana Ferrari Read Post »

Recording of the December 8, 2023 ERN-LUNG webinar on quality Indicators for pulmonary arterial hypertension is available

On December the 8th 2023 the European Reference Network for Rare Lung Diseases (ERN-Lung) hosted a webinar titled “Quality Indicators in Healthcare, the example of Pulmonary Hypertension”. The webinar refers to the scientific paper on quality indicators published in the European Journal of Heart Failure, in connection with the publication of the 2022 European Society

Recording of the December 8, 2023 ERN-LUNG webinar on quality Indicators for pulmonary arterial hypertension is available Read Post »

Prof. Frances de Man has been awarded a grant from the Dutch Heart Foundation for her research on the prevention of right heart failure in pulmonary hypertension

The Dutch Heart Foundation has awarded an “Established Investigator” grant to Prof. Dr. Frances de Man from the Amsterdam UMC. She is conducting research to better understand and prevent right heart failure in pulmonary hypertension. When the blood pressure in the lungs is too high (in pulmonary hypertension), the right ventricle has to work harder

Prof. Frances de Man has been awarded a grant from the Dutch Heart Foundation for her research on the prevention of right heart failure in pulmonary hypertension Read Post »

Wrapping up a successful year of pulmonary hypertension knowledge-sharing educational live web events!

The Alliance for Pulmonary Hypertension has just held the last webinar of the six-part series it launched in June 2023 exploring the innovations outlined in the 2022 joint clinical guidelines on pulmonary hypertension by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Across these six insightful sessions, we delved into pivotal

Wrapping up a successful year of pulmonary hypertension knowledge-sharing educational live web events! Read Post »

The European Medicines Agency (EMA) has issued a call for patient representatives to join the Committee for Orphan Medicinal Products (COMP)

The European Commission has launched a call for expressions of interest to represent patients’ organisations in European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP). This is a very important opportunity for patients to have a role in the approval of orphan medicinal products! The call aims to fill three positions nominated by the

The European Medicines Agency (EMA) has issued a call for patient representatives to join the Committee for Orphan Medicinal Products (COMP) Read Post »

TRANSLATE »
Scroll to Top